Avistone Biotechnology
Privately held: no public share price
Assets
(3 total)
3Total Assets
0Approved
2Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | EGFRSmall molecule | Non-Small Cell Lung Cancer | |
| Phase 3 | METSmall molecule | Non-Small Cell Lung CancerGlioma Non-Small Cell Lung Cancer with MET Exon 14 Skipping | |
| Phase 1/2 | EGFRSmall molecule | Non-Small Cell Lung Cancer |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
2027 (1)
December 2027 (1)
Est. primary completion 2027-12-31 · NCT06970782 · CT.gov ↗
What to watch
2028 (1)
June 2028 (1)
Est. primary completion 2028-06-30 · NCT06281964 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.